BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 12015982)

  • 1. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression.
    Pelengaris S; Khan M; Evan GI
    Cell; 2002 May; 109(3):321-34. PubMed ID: 12015982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic co-operation in beta-cell tumorigenesis.
    Pelengaris S; Khan M
    Endocr Relat Cancer; 2001 Dec; 8(4):307-14. PubMed ID: 11733227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta.
    Shchors K; Shchors E; Rostker F; Lawlor ER; Brown-Swigart L; Evan GI
    Genes Dev; 2006 Sep; 20(18):2527-38. PubMed ID: 16980582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis.
    Pelengaris S; Abouna S; Cheung L; Ifandi V; Zervou S; Khan M
    BMC Biol; 2004 Dec; 2():26. PubMed ID: 15613240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of c-Myc activity and apoptosis in vivo.
    Alarcon RM; Rupnow BA; Graeber TG; Knox SJ; Giaccia AJ
    Cancer Res; 1996 Oct; 56(19):4315-9. PubMed ID: 8813114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice.
    Blyth K; Stewart M; Bell M; James C; Evan G; Neil JC; Cameron ER
    Oncogene; 2000 Feb; 19(6):773-82. PubMed ID: 10698495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.
    Lawlor ER; Soucek L; Brown-Swigart L; Shchors K; Bialucha CU; Evan GI
    Cancer Res; 2006 May; 66(9):4591-601. PubMed ID: 16651409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice.
    de La Coste A; Mignon A; Fabre M; Gilbert E; Porteu A; Van Dyke T; Kahn A; Perret C
    Cancer Res; 1999 Oct; 59(19):5017-22. PubMed ID: 10519417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion.
    Pelengaris S; Littlewood T; Khan M; Elia G; Evan G
    Mol Cell; 1999 May; 3(5):565-77. PubMed ID: 10360173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of c-MYC activation on glucose stimulus-secretion coupling events in mouse pancreatic islets.
    Pascal SM; Guiot Y; Pelengaris S; Khan M; Jonas JC
    Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E92-102. PubMed ID: 18413670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells.
    Kang Y; Cortina R; Perry RR
    J Natl Cancer Inst; 1996 Mar; 88(5):279-84. PubMed ID: 8614006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omomyc expression in skin prevents Myc-induced papillomatosis.
    Soucek L; Nasi S; Evan GI
    Cell Death Differ; 2004 Sep; 11(9):1038-45. PubMed ID: 15143346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Myc shares cellular functions wiht c-Myc.
    Aubry S; Charron J
    DNA Cell Biol; 2000 Jun; 19(6):353-64. PubMed ID: 10882234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis and differentiation of human embryonic stem cells induced by sustained activation of c-Myc.
    Sumi T; Tsuneyoshi N; Nakatsuji N; Suemori H
    Oncogene; 2007 Aug; 26(38):5564-76. PubMed ID: 17369859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
    Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
    Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
    Raha P; Thomas S; Thurn KT; Park J; Munster PN
    Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent.
    Trudel M; Lanoix J; Barisoni L; Blouin MJ; Desforges M; L'Italien C; D'Agati V
    J Exp Med; 1997 Dec; 186(11):1873-84. PubMed ID: 9382886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
    Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
    Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of AP-1 transcription activator induces myc-dependent apoptosis in HL60 cells.
    Park S; Hahm ER; Lee DK; Yang CH
    J Cell Biochem; 2004 Apr; 91(5):973-86. PubMed ID: 15034932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
    Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
    Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.